推荐产品
生物源
synthetic
等級
pharmaceutical primary standard
agency
EP
API 家族
dihydrotachysterol
形狀
solid
製造商／商標名
EDQM
技術
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
mp
113-127 °C
應用
pharmaceutical (small molecule)
格式
neat
儲存溫度
−20°C
SMILES 字串
C[C@@H]([C@@]1([H])CC[C@@]2([H])/C(CCC[C@@]21C)=C/C=C3[C@@H](C)CC[C@H](O)C/3)/C=C/[C@H](C)C(C)C
InChI
1S/C28H46O/c1-19(2)20(3)12-13-22(5)25-16-17-26-23(10-8-18-28(25,26)6)14-15-24-21(4)9-7-11-27(24)29/h12-15,19-22,25-27,29H,7-11,16-18H2,1-6H3/b13-12+,23-14+,24-15+/t20-,21-,22+,25?,26?,27-,28+/m0/s1
InChI 密鑰
DTSXXSAWQHPLEF-GFVAUXBKSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. Dihydrotachysterol (DHT) is a biologically active synthetic analog of vitamin D. It aids in promoting active calcium and phosphate intestinal absorption. It is also beneficial in the treatment of hypoparathyroidism.
應用
Dihydrotachysterol for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
Sales restrictions may apply.
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 3 Oral - Aquatic Chronic 4
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
I Quack et al.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 113(7), 376-380 (2005-07-19)
The half synthetic Vitamin D analogue dihydrotachysterol (DHT) is widely used for hypocalcaemic hypoparathyroidism following surgical removal of parathyroids. Such treatment generally initiated by surgeons right after surgery has to be continued in clinical practice. Unfortunately, the required careful monitoring
A L Voigts et al.
Archives of internal medicine, 143(5), 960-963 (1983-05-01)
The available data with regard to the use of calciferol, dihydrotachysterol, and calcifediol in the management of renal insufficiency are reviewed. Very limited data are available with regard to calciferol therapy; with the advent of more active metabolites, the use
In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha, 25-and 1 beta, 25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity.
Qaw F, et al.
Test, 268(1), 282-292 (1993)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门